<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220113053705N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-07-06</date_registration>
      <primary_sponsor>Sanandaj University of Medical Sciences</primary_sponsor>
      <public_title>The effectiveness of Minfdul Interoceptive Exposure on improvement of OCD symptoms</public_title>
      <acronym></acronym>
      <scientific_title>The effectiveness of Minfdul Interoceptive Exposure on improvement of symptoms of patients with Obsessive Compulsive Disorder</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-07-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/84536</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: After identifying and selecting eligible participants, they will be randomly assigned to the study groups through a lottery method. Specifically, the participants’ names will be written on identical cards, which will then be randomly drawn from a designated container to divide the individuals into intervention and control groups. This approach is used to eliminate any potential bias in the allocation process and to enhance the internal validity of the study, Blinding description: During the data analysis phase, the clinical evaluator or researcher reviewing the data is kept unaware of the participants' group assignments and their characteristics. The data are coded or anonymized in a way that prevents the evaluator from identifying which data belongs to which group. This procedure helps prevent evaluator bias in interpreting and assessing the data, thereby enhancing the validity of the study results.</study_design>
      <phase>3</phase>
      <hc_freetext>Obsessive-Compulsive Disorder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The intervention group receives mindfulness-based exposure therapy as the treatment, which consists of four therapy sessions with specific goals and strategies. Details of the weekly sessions are provided in Table 1. This therapy is a third-wave cognitive-behavioral treatment and is one of the transdiagnostic approaches that utilize mindfulness skill training along with cognitive-behavioral techniques. All sessions (Sessions 1–8) are outlined according to the relevant protocol (Sohrabi et al., 2024; Kiyon, 2011; Kiyon, Francis &amp; Shirz, 2018).The primary goal of the therapy, following the therapeutic contract and client preparation, is to facilitate the process of change, which continues with several main objectives pursued across multiple sessions. The first phase is introversion, which focuses on developing attention skills, attention restoration, and attention regulation within the context of emotion regulation, using mindfulness techniques.Next, in the extroversion phase, the learned skills provide a basis for confronting intrapersonal problems, employing mindful exposure techniques to address harmful personal contexts. Then, as skills expand, the interpersonal and extrapersonal phases broaden this confrontation to wider interpersonal contexts. Finally, these stages are integrated into a comprehensive therapeutic package. Intervention 2: Control group: After being assigned to the control group, participants do not receive any specific psychotherapeutic intervention concurrently and continue to receive only their usual medication treatment.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data related to the study will be provided in response to legitimate requests from the relevant organizations.

When:
After publication of the data

To whom:
Academic researchers can access the data upon submitting a formal and justified request.

Conditions:
The individual must have a verified identity and submit the request through an official or academic organization. They must accept responsibility for maintaining confidentiality and not disclosing the data without permission, in accordance with ethical principles.

Where to obtain:
They can correspond via the following email to make a request:
F.sohrabi20@gmail.com

How to obtain:
After receiving the email and reviewing it through official channels, the request will be responded to as soon as possible.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fateh Sohrabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Clinical Psychology Branch, Faculty of Medicine, Kurdistan University of Medical Sciences, Pasdaran Ave.</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6617713446</zip>
        <telephone>+98 87 3366 4664</telephone>
        <email>f.sohrabi20@gmail.com</email>
        <affiliation>Sanandaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fateh Sohrabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Clinical Psychology Branch, Faculty of Medicine, Kurdistan University of Medical Sciences, Pasdaran Ave.</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6617713446</zip>
        <telephone>+98 87 3366 4664</telephone>
        <email>F.sohrabi20@gmail.com</email>
        <affiliation>Sanandaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>•  Willingness to participate in the study
•  Ability to read and write at a middle school level
•  Diagnosis of obsessive-compulsive disorder (OCD) based on a psychiatric evaluation
•  Not currently undergoing any psychotherapy
•  No changes in medication during the psychotherapy period</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>•  Presence of a psychotic disorder or lack of insight in OCD
•  Having intellectual or cognitive impairments such as intellectual disability, dementia, or delirium
•  Concurrent substance use disorders</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F42</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Obsessive-compulsive disorder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The intervention group receives mindfulness-based exposure therapy as the treatment, which consists of four therapy sessions with specific goals and strategies. Details of the weekly sessions are provided in Table 1. This therapy is a third-wave cognitive-behavioral treatment and is one of the transdiagnostic approaches that utilize mindfulness skill training along with cognitive-behavioral techniques. All sessions (Sessions 1–8) are outlined according to the relevant protocol (Sohrabi et al., 2024; Kiyon, 2011; Kiyon, Francis &amp; Shirz, 2018).The primary goal of the therapy, following the therapeutic contract and client preparation, is to facilitate the process of change, which continues with several main objectives pursued across multiple sessions. The first phase is introversion, which focuses on developing attention skills, attention restoration, and attention regulation within the context of emotion regulation, using mindfulness techniques.Next, in the extroversion phase, the learned skills provide a basis for confronting intrapersonal problems, employing mindful exposure techniques to address harmful personal contexts. Then, as skills expand, the interpersonal and extrapersonal phases broaden this confrontation to wider interpersonal contexts. Finally, these stages are integrated into a comprehensive therapeutic package.</i_keyword>
      <i_keyword>Control group: After being assigned to the control group, participants do not receive any specific psychotherapeutic intervention concurrently and continue to receive only their usual medication treatment.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Timepoint: Before the intervention starts – after completing the treatment sessions – and three months after the last session. Method of measurement: Yale-Brown Obsessive Compulsive Scale (Y-BOCS).</prim_outcome>
      <prim_outcome>Anxiety Sensitivity Index-3. Timepoint: Before the intervention starts – after completing the treatment sessions – and three months after the last session. Method of measurement: Anxiety Sensitivity Index-3.</prim_outcome>
      <prim_outcome>Multidimensional Assessment of Interoceptive Awareness-2. Timepoint: Before the intervention starts – after completing the treatment sessions – and three months after the last session. Method of measurement: Multidimensional Assessment of Interoceptive Awareness-2.</prim_outcome>
      <prim_outcome>Depression, Anxiety and Stress scale. Timepoint: Before the intervention starts – after completing the treatment sessions – and three months after the last session. Method of measurement: Depression, Anxiety and Stress scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>kurdistan University Of medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-06-10</approval_date>
        <contact_name>research ethics committees of Kurdistan university of medical sciences</contact_name>
        <contact_address>Faculty of Medicine, Kurdistan University of Medical Sciences, Pasdaran Ave. Sanandaj Kurdistan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
